Approvals & regulatory · first seen 1h ago, updated 1h ago
EC approves first treatment for rare neurodegenerative disease
The European Commission (EC) has granted marketing authorisation under exceptional circumstances for Nezglyal (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients. I…
Summary from DDW Drug Discovery World.
Coverage 1 article · 1 outlet
-
DDW Drug Discovery WorldEC approves first treatment for rare neurodegenerative disease